ID   GBP1_HUMAN              Reviewed;         592 AA.
AC   P32455; D3DT26; Q5T8M1;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   02-NOV-2010, sequence version 2.
DT   28-JUN-2023, entry version 197.
DE   RecName: Full=Guanylate-binding protein 1 {ECO:0000305};
DE            EC=3.6.1.- {ECO:0000269|PubMed:16511497};
DE            EC=3.6.5.- {ECO:0000269|PubMed:10676968, ECO:0000269|PubMed:16511497};
DE   AltName: Full=GTP-binding protein 1 {ECO:0000303|PubMed:8830800};
DE            Short=GBP-1 {ECO:0000303|PubMed:8830800};
DE            Short=HuGBP-1 {ECO:0000303|PubMed:8830800};
DE            Short=hGBP1 {ECO:0000303|PubMed:7512561};
DE   AltName: Full=Guanine nucleotide-binding protein 1;
DE   AltName: Full=Interferon-induced guanylate-binding protein 1 {ECO:0000303|PubMed:1715024};
DE   Flags: Precursor;
GN   Name=GBP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS SER-349 AND GLY-409.
RX   PubMed=1715024; DOI=10.1128/mcb.11.9.4717-4725.1991;
RA   Cheng Y.-S.E., Patterson C.E., Staeheli P.;
RT   "Interferon-induced guanylate-binding proteins lack an N(T)KXD consensus
RT   motif and bind GMP in addition to GDP and GTP.";
RL   Mol. Cell. Biol. 11:4717-4725(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS SER-349 AND GLY-409.
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS SER-349 AND GLY-409.
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=7512561; DOI=10.1016/s0021-9258(19)78125-3;
RA   Schwemmle M., Staeheli P.;
RT   "The interferon-induced 67-kDa guanylate-binding protein (hGBP1) is a
RT   GTPase that converts GTP to GMP.";
RL   J. Biol. Chem. 269:11299-11305(1994).
RN   [8]
RP   ISOPRENYLATION AT CYS-589, AND METHYLATION AT CYS-589.
RX   PubMed=8830800; DOI=10.1002/jlb.60.3.423;
RA   Nantais D.E., Schwemmle M., Stickney J.T., Vestal D.J., Buss J.E.;
RT   "Prenylation of an interferon-gamma-induced GTP-binding protein: the human
RT   guanylate binding protein, huGBP1.";
RL   J. Leukoc. Biol. 60:423-431(1996).
RN   [9]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15937107; DOI=10.1073/pnas.0503227102;
RA   Modiano N., Lu Y.E., Cresswell P.;
RT   "Golgi targeting of human guanylate-binding protein-1 requires nucleotide
RT   binding, isoprenylation, and an IFN-gamma-inducible cofactor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:8680-8685(2005).
RN   [10]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16936281; DOI=10.2353/ajpath.2006.060244;
RA   Naschberger E., Lubeseder-Martellato C., Meyer N., Gessner R., Kremmer E.,
RA   Gessner A., Sturzl M.;
RT   "Human guanylate binding protein-1 is a secreted GTPase present in
RT   increased concentrations in the cerebrospinal fluid of patients with
RT   bacterial meningitis.";
RL   Am. J. Pathol. 169:1088-1099(2006).
RN   [11]
RP   SUBCELLULAR LOCATION, AND INDUCTION.
RX   PubMed=17266443; DOI=10.1089/jir.2007.0086;
RA   Tripal P., Bauer M., Naschberger E., Mortinger T., Hohenadl C., Cornali E.,
RA   Thurau M., Sturzl M.;
RT   "Unique features of different members of the human guanylate-binding
RT   protein family.";
RL   J. Interferon Cytokine Res. 27:44-52(2007).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   SUBCELLULAR LOCATION, DIMERIZATION, ISOPRENYLATION, AND MUTAGENESIS OF
RP   LYS-51; 227-ARG-LYS-228 AND 589-CYS--SER-592.
RX   PubMed=21151871; DOI=10.1371/journal.pone.0014246;
RA   Britzen-Laurent N., Bauer M., Berton V., Fischer N., Syguda A.,
RA   Reipschlager S., Naschberger E., Herrmann C., Sturzl M.;
RT   "Intracellular trafficking of guanylate-binding proteins is regulated by
RT   heterodimerization in a hierarchical manner.";
RL   PLoS ONE 5:E14246-E14246(2010).
RN   [14]
RP   FUNCTION.
RX   PubMed=22106366; DOI=10.1096/fj.11-189886;
RA   Nordmann A., Wixler L., Boergeling Y., Wixler V., Ludwig S.;
RT   "A new splice variant of the human guanylate-binding protein 3 mediates
RT   anti-influenza activity through inhibition of viral transcription and
RT   replication.";
RL   FASEB J. 26:1290-1300(2012).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, ISOPRENYLATION, AND MUTAGENESIS OF ARG-48 AND
RP   LYS-76.
RX   PubMed=28645896; DOI=10.1073/pnas.1620959114;
RA   Shydlovskyi S., Zienert A.Y., Ince S., Dovengerds C., Hohendahl A.,
RA   Dargazanli J.M., Blum A., Guenther S.D., Kladt N., Stuerzl M.,
RA   Schauss A.C., Kutsch M., Roux A., Praefcke G.J.K., Herrmann C.;
RT   "Nucleotide-dependent farnesyl switch orchestrates polymerization and
RT   membrane binding of human guanylate-binding protein 1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:E5559-E5568(2017).
RN   [16]
RP   UBIQUITINATION (MICROBIAL INFECTION).
RX   PubMed=29024643; DOI=10.1016/j.chom.2017.09.007;
RA   Wandel M.P., Pathe C., Werner E.I., Ellison C.J., Boyle K.B.,
RA   von der Malsburg A., Rohde J., Randow F.;
RT   "GBPs inhibit motility of Shigella flexneri but are targeted for
RT   degradation by the bacterial ubiquitin ligase IpaH9.8.";
RL   Cell Host Microbe 22:507-518(2017).
RN   [17]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF 584-ARG--ARG-586.
RX   PubMed=29233899; DOI=10.1128/mbio.01979-17;
RA   Piro A.S., Hernandez D., Luoma S., Feeley E.M., Finethy R., Yirga A.,
RA   Frickel E.M., Lesser C.F., Coers J.;
RT   "Detection of cytosolic Shigella flexneri via a C-terminal triple-arginine
RT   motif of GBP1 inhibits actin-based motility.";
RL   MBio 8:0-0(2017).
RN   [18]
RP   UBIQUITINATION AT LYS-207; LYS-209; LYS-210; LYS-382; LYS-562; LYS-567;
RP   LYS-573 AND LYS-587 (MICROBIAL INFECTION), FUNCTION, ISOPRENYLATION AT
RP   CYS-589, AND MUTAGENESIS OF ARG-48; ASP-184; LYS-207; LYS-209; LYS-210;
RP   LYS-382; LYS-562; LYS-567; LYS-573; LYS-587 AND CYS-589.
RX   PubMed=29144452; DOI=10.1038/nature24467;
RA   Li P., Jiang W., Yu Q., Liu W., Zhou P., Li J., Xu J., Xu B., Wang F.,
RA   Shao F.;
RT   "Ubiquitination and degradation of GBPs by a Shigella effector to suppress
RT   host defence.";
RL   Nature 551:378-383(2017).
RN   [19]
RP   FUNCTION, SUBCELLULAR LOCATION, ISOPRENYLATION AT CYS-589, AND MUTAGENESIS
RP   OF LYS-51; 227-ARG-LYS-228 AND CYS-589.
RX   PubMed=31268602; DOI=10.15252/embj.2018100926;
RA   Fisch D., Bando H., Clough B., Hornung V., Yamamoto M., Shenoy A.R.,
RA   Frickel E.M.;
RT   "Human GBP1 is a microbe-specific gatekeeper of macrophage apoptosis and
RT   pyroptosis.";
RL   EMBO J. 38:e100926-e100926(2019).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS), AND GTP-BINDING.
RX   PubMed=10676968; DOI=10.1038/35000617;
RA   Prakash B., Praefcke G.J.K., Renault L., Wittinghofer A., Herrmann C.;
RT   "Structure of human guanylate-binding protein 1 representing a unique class
RT   of GTP-binding proteins.";
RL   Nature 403:567-571(2000).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) IN COMPLEX WITH GTP ANALOG, AND
RP   GTP-BINDING.
RX   PubMed=10970849; DOI=10.1093/emboj/19.17.4555;
RA   Prakash B., Renault L., Praefcke G.J., Herrmann C., Wittinghofer A.;
RT   "Triphosphate structure of guanylate-binding protein 1 and implications for
RT   nucleotide binding and GTPase mechanism.";
RL   EMBO J. 19:4555-4564(2000).
RN   [22] {ECO:0007744|PDB:2B8W, ECO:0007744|PDB:2B92, ECO:0007744|PDB:2BC9, ECO:0007744|PDB:2D4H}
RP   X-RAY CRYSTALLOGRAPHY (2.22 ANGSTROMS) OF 1-317 IN COMPLEX WITH GDP AND
RP   GMP, FUNCTION, CATALYTIC ACTIVITY, AND SUBUNIT.
RX   PubMed=16511497; DOI=10.1038/nature04510;
RA   Ghosh A., Praefcke G.J., Renault L., Wittinghofer A., Herrmann C.;
RT   "How guanylate-binding proteins achieve assembly-stimulated processive
RT   cleavage of GTP to GMP.";
RL   Nature 440:101-104(2006).
RN   [23] {ECO:0007744|PDB:6K1Z, ECO:0007744|PDB:6K2D}
RP   X-RAY CRYSTALLOGRAPHY (2.31 ANGSTROMS) IN COMPLEX WITH S.FLEXNERI IPAH9.8,
RP   AND UBIQUITINATION (MICROBIAL INFECTION).
RX   PubMed=31216343; DOI=10.1371/journal.ppat.1007876;
RA   Ji C., Du S., Li P., Zhu Q., Yang X., Long C., Yu J., Shao F., Xiao J.;
RT   "Structural mechanism for guanylate-binding proteins (GBPs) targeting by
RT   the Shigella E3 ligase IpaH9.8.";
RL   PLoS Pathog. 15:e1007876-e1007876(2019).
RN   [24] {ECO:0007744|PDB:6LOJ}
RP   X-RAY CRYSTALLOGRAPHY (3.72 ANGSTROMS) IN COMPLEX WITH S.FLEXNERI IPAH9.8,
RP   AND UBIQUITINATION (MICROBIAL INFECTION).
RX   PubMed=33303953; DOI=10.1038/s42003-020-01492-1;
RA   Ye Y., Xiong Y., Huang H.;
RT   "Substrate-binding destabilizes the hydrophobic cluster to relieve the
RT   autoinhibition of bacterial ubiquitin ligase IpaH9.8.";
RL   Commun. Biol. 3:752-752(2020).
CC   -!- FUNCTION: Interferon (IFN)-inducible GTPase that plays important roles
CC       in innate immunity against a diverse range of bacterial, viral and
CC       protozoan pathogens (PubMed:22106366, PubMed:29144452, PubMed:16511497,
CC       PubMed:31268602). Hydrolyzes GTP to GMP in two consecutive cleavage
CC       reactions: GTP is first hydrolyzed to GDP and then to GMP in a
CC       processive manner (PubMed:7512561, PubMed:16511497). Following
CC       infection, recruited to the pathogen-containing vacuoles or vacuole-
CC       escaped bacteria and promotes both autophagy and inflammasome assembly
CC       (PubMed:29144452, PubMed:31268602). Promotes host defense against
CC       bacterial infections by regulating bacteriolytic peptide generation via
CC       its interaction with ubiquitin-binding protein SQSTM1, which delivers
CC       monoubiquitinated proteins to autolysosomes for the generation of
CC       bacteriolytic peptides (By similarity). Also acts as a positive
CC       regulator of inflammasome assembly by promoting the release of
CC       inflammasome ligands from bacteria (PubMed:31268602). Acts by promoting
CC       lysis of pathogen-containing vacuoles, releasing pathogens into the
CC       cytosol (By similarity). Following pathogen release in the cytosol,
CC       promotes recruitment of proteins that mediate bacterial cytolysis: this
CC       liberates ligands that are detected by inflammasomes, such as
CC       lipopolysaccharide (LPS) that activates the non-canonical CASP4/CASP11
CC       inflammasome or double-stranded DNA (dsDNA) that activates the AIM2
CC       inflammasome (PubMed:31268602). Confers protection to several
CC       pathogens, including the bacterial pathogens L.monocytogenes and
CC       M.bovis BCG as well as the protozoan pathogen T.gondii
CC       (PubMed:31268602). Exhibits antiviral activity against influenza virus
CC       (PubMed:22106366). {ECO:0000250|UniProtKB:Q01514,
CC       ECO:0000269|PubMed:16511497, ECO:0000269|PubMed:22106366,
CC       ECO:0000269|PubMed:29144452, ECO:0000269|PubMed:31268602,
CC       ECO:0000269|PubMed:7512561}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=GTP + H2O = GDP + H(+) + phosphate; Xref=Rhea:RHEA:19669,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:37565,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:58189;
CC         Evidence={ECO:0000269|PubMed:10676968, ECO:0000269|PubMed:16511497,
CC         ECO:0000269|PubMed:28645896};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:19670;
CC         Evidence={ECO:0000269|PubMed:10676968, ECO:0000269|PubMed:16511497,
CC         ECO:0000269|PubMed:28645896};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=GDP + H2O = GMP + H(+) + phosphate; Xref=Rhea:RHEA:22156,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:58115, ChEBI:CHEBI:58189;
CC         Evidence={ECO:0000269|PubMed:16511497, ECO:0000269|PubMed:28645896};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:22157;
CC         Evidence={ECO:0000269|PubMed:16511497, ECO:0000269|PubMed:28645896};
CC   -!- SUBUNIT: Homodimer; homodimerization occurs upon GTP-binding and is
CC       required for the second hydrolysis step from GDP to GMP
CC       (PubMed:10970849, PubMed:16511497). Undergoes conformational changes
CC       and oligomerization upon GTP-binding and hydrolysis (PubMed:28645896).
CC       Heterodimer with other family members, including GBP2, GBP3, GBP4 and
CC       GBP5 (PubMed:10970849, PubMed:16511497). Dimerization regulates
CC       subcellular location to membranous structures (PubMed:21151871).
CC       Interacts with SQSTM1 (By similarity). {ECO:0000250|UniProtKB:Q01514,
CC       ECO:0000269|PubMed:10970849, ECO:0000269|PubMed:16511497,
CC       ECO:0000269|PubMed:21151871, ECO:0000269|PubMed:28645896}.
CC   -!- INTERACTION:
CC       P32455; P32455: GBP1; NbExp=15; IntAct=EBI-2869161, EBI-2869161;
CC       P32455; P32456: GBP2; NbExp=9; IntAct=EBI-2869161, EBI-714388;
CC       P32455; Q9H0R5: GBP3; NbExp=3; IntAct=EBI-2869161, EBI-2798916;
CC       P32455; Q96PP9: GBP4; NbExp=2; IntAct=EBI-2869161, EBI-20840650;
CC       P32455; Q96PP8: GBP5; NbExp=9; IntAct=EBI-2869161, EBI-749932;
CC   -!- SUBCELLULAR LOCATION: Cytoplasmic vesicle membrane
CC       {ECO:0000269|PubMed:29144452, ECO:0000269|PubMed:29233899,
CC       ECO:0000269|PubMed:31268602}; Lipid-anchor
CC       {ECO:0000269|PubMed:21151871}; Cytoplasmic side
CC       {ECO:0000269|PubMed:21151871}. Golgi apparatus membrane
CC       {ECO:0000269|PubMed:15937107}; Lipid-anchor
CC       {ECO:0000269|PubMed:21151871}; Cytoplasmic side
CC       {ECO:0000269|PubMed:21151871}. Cell membrane
CC       {ECO:0000269|PubMed:21151871}; Lipid-anchor
CC       {ECO:0000269|PubMed:21151871}; Cytoplasmic side
CC       {ECO:0000269|PubMed:21151871}. Cytoplasm {ECO:0000269|PubMed:21151871}.
CC       Secreted {ECO:0000269|PubMed:16936281}. Note=Localizes to pathogen-
CC       containing vacuoles or to the cell surface of bacteria that escaped
CC       vacuoles (PubMed:29144452, PubMed:31268602). Secreted from endothelial
CC       cells in the cerebrospinal fluid, upon bacterial challenge and
CC       independently of IFNG induction (PubMed:16936281). Golgi membrane
CC       localization requires isoprenylation and the presence of another IFNG-
CC       induced factor (PubMed:15937107). {ECO:0000269|PubMed:15937107,
CC       ECO:0000269|PubMed:16936281, ECO:0000269|PubMed:29144452,
CC       ECO:0000269|PubMed:31268602}.
CC   -!- INDUCTION: By IFNG during macrophage activation, and by TNF and IL1B.
CC       {ECO:0000269|PubMed:17266443}.
CC   -!- PTM: Isoprenylation is required for proper subcellular location.
CC       {ECO:0000269|PubMed:21151871, ECO:0000269|PubMed:28645896,
CC       ECO:0000269|PubMed:31268602}.
CC   -!- PTM: (Microbial infection) Ubiquitinated by S.flexneri IpaH9.8, leading
CC       to its degradation by the proteasome, thereby preventing its ability to
CC       promote host defense against bacterial infection.
CC       {ECO:0000269|PubMed:29024643, ECO:0000269|PubMed:29144452,
CC       ECO:0000269|PubMed:31216343, ECO:0000269|PubMed:33303953}.
CC   -!- SIMILARITY: Belongs to the TRAFAC class dynamin-like GTPase
CC       superfamily. GB1/RHD3 GTPase family. GB1 subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU01052}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/50147/GBP1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M55542; AAA35871.1; -; mRNA.
DR   EMBL; BT006847; AAP35493.1; -; mRNA.
DR   EMBL; AK291783; BAF84472.1; -; mRNA.
DR   EMBL; AL160008; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471097; EAW73148.1; -; Genomic_DNA.
DR   EMBL; CH471097; EAW73150.1; -; Genomic_DNA.
DR   EMBL; BC002666; AAH02666.1; -; mRNA.
DR   CCDS; CCDS718.1; -.
DR   PIR; A41268; A41268.
DR   RefSeq; NP_002044.2; NM_002053.2.
DR   PDB; 1DG3; X-ray; 1.80 A; A=1-592.
DR   PDB; 1F5N; X-ray; 1.70 A; A=1-592.
DR   PDB; 2B8W; X-ray; 2.22 A; A/B=1-317.
DR   PDB; 2B92; X-ray; 3.20 A; A/B=1-317.
DR   PDB; 2BC9; X-ray; 2.80 A; A=1-317.
DR   PDB; 2D4H; X-ray; 2.90 A; A/B=1-317.
DR   PDB; 6K1Z; X-ray; 2.31 A; A=1-592.
DR   PDB; 6K2D; X-ray; 3.60 A; A=1-479.
DR   PDB; 6LOJ; X-ray; 3.72 A; B=1-592.
DR   PDBsum; 1DG3; -.
DR   PDBsum; 1F5N; -.
DR   PDBsum; 2B8W; -.
DR   PDBsum; 2B92; -.
DR   PDBsum; 2BC9; -.
DR   PDBsum; 2D4H; -.
DR   PDBsum; 6K1Z; -.
DR   PDBsum; 6K2D; -.
DR   PDBsum; 6LOJ; -.
DR   AlphaFoldDB; P32455; -.
DR   SASBDB; P32455; -.
DR   SMR; P32455; -.
DR   BioGRID; 108903; 40.
DR   DIP; DIP-60423N; -.
DR   IntAct; P32455; 13.
DR   MINT; P32455; -.
DR   STRING; 9606.ENSP00000359504; -.
DR   iPTMnet; P32455; -.
DR   MetOSite; P32455; -.
DR   PhosphoSitePlus; P32455; -.
DR   SwissPalm; P32455; -.
DR   BioMuta; GBP1; -.
DR   DMDM; 311033383; -.
DR   EPD; P32455; -.
DR   jPOST; P32455; -.
DR   MassIVE; P32455; -.
DR   MaxQB; P32455; -.
DR   PaxDb; P32455; -.
DR   PeptideAtlas; P32455; -.
DR   ProteomicsDB; 54877; -.
DR   Antibodypedia; 4224; 346 antibodies from 34 providers.
DR   DNASU; 2633; -.
DR   Ensembl; ENST00000370473.5; ENSP00000359504.4; ENSG00000117228.11.
DR   GeneID; 2633; -.
DR   KEGG; hsa:2633; -.
DR   MANE-Select; ENST00000370473.5; ENSP00000359504.4; NM_002053.3; NP_002044.2.
DR   UCSC; uc001dmx.3; human.
DR   AGR; HGNC:4182; -.
DR   CTD; 2633; -.
DR   DisGeNET; 2633; -.
DR   GeneCards; GBP1; -.
DR   HGNC; HGNC:4182; GBP1.
DR   HPA; ENSG00000117228; Tissue enhanced (liver).
DR   MIM; 600411; gene.
DR   neXtProt; NX_P32455; -.
DR   OpenTargets; ENSG00000117228; -.
DR   PharmGKB; PA28596; -.
DR   VEuPathDB; HostDB:ENSG00000117228; -.
DR   eggNOG; KOG2037; Eukaryota.
DR   GeneTree; ENSGT00940000156840; -.
DR   HOGENOM; CLU_018608_2_2_1; -.
DR   InParanoid; P32455; -.
DR   OMA; CDMDDQE; -.
DR   OrthoDB; 5309032at2759; -.
DR   PhylomeDB; P32455; -.
DR   TreeFam; TF331602; -.
DR   PathwayCommons; P32455; -.
DR   Reactome; R-HSA-877300; Interferon gamma signaling.
DR   SignaLink; P32455; -.
DR   BioGRID-ORCS; 2633; 22 hits in 1144 CRISPR screens.
DR   ChiTaRS; GBP1; human.
DR   EvolutionaryTrace; P32455; -.
DR   GeneWiki; GBP1; -.
DR   GenomeRNAi; 2633; -.
DR   Pharos; P32455; Tbio.
DR   PRO; PR:P32455; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P32455; protein.
DR   Bgee; ENSG00000117228; Expressed in pericardium and 194 other tissues.
DR   Genevisible; P32455; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:UniProt.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0106139; C:symbiont cell surface; IDA:UniProtKB.
DR   GO; GO:0012506; C:vesicle membrane; IDA:UniProtKB.
DR   GO; GO:0003779; F:actin binding; IDA:UniProtKB.
DR   GO; GO:0019955; F:cytokine binding; IPI:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0003925; F:G protein activity; IDA:UniProtKB.
DR   GO; GO:0019003; F:GDP binding; IDA:CAFA.
DR   GO; GO:0004382; F:GDP phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0005525; F:GTP binding; IDA:UniProtKB.
DR   GO; GO:0003924; F:GTPase activity; IDA:UniProtKB.
DR   GO; GO:0051879; F:Hsp90 protein binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0030507; F:spectrin binding; IPI:UniProtKB.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEP:UniProtKB.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEP:UniProtKB.
DR   GO; GO:0071346; P:cellular response to type II interferon; IDA:UniProtKB.
DR   GO; GO:0051715; P:cytolysis in another organism; IDA:UniProtKB.
DR   GO; GO:0042742; P:defense response to bacterium; ISS:UniProtKB.
DR   GO; GO:0042832; P:defense response to protozoan; IDA:UniProtKB.
DR   GO; GO:0051607; P:defense response to virus; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; IDA:UniProtKB.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0032703; P:negative regulation of interleukin-2 production; IMP:UniProtKB.
DR   GO; GO:1903077; P:negative regulation of protein localization to plasma membrane; IMP:UniProtKB.
DR   GO; GO:1900025; P:negative regulation of substrate adhesion-dependent cell spreading; IMP:UniProtKB.
DR   GO; GO:0050860; P:negative regulation of T cell receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0160075; P:non-canonical inflammasome complex assembly; IDA:UniProt.
DR   GO; GO:0140639; P:positive regulation of pyroptosis; IDA:UniProtKB.
DR   GO; GO:0072665; P:protein localization to vacuole; IDA:UniProtKB.
DR   GO; GO:0050848; P:regulation of calcium-mediated signaling; IMP:UniProtKB.
DR   GO; GO:1903076; P:regulation of protein localization to plasma membrane; IGI:UniProtKB.
DR   CDD; cd01851; GBP; 1.
DR   CDD; cd16269; GBP_C; 1.
DR   Gene3D; 1.20.1000.10; Guanylate-binding protein, C-terminal domain; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   InterPro; IPR030386; G_GB1_RHD3_dom.
DR   InterPro; IPR037684; GBP_C.
DR   InterPro; IPR003191; Guanylate-bd/ATL_C.
DR   InterPro; IPR036543; Guanylate-bd_C_sf.
DR   InterPro; IPR015894; Guanylate-bd_N.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR10751; GUANYLATE BINDING PROTEIN; 1.
DR   PANTHER; PTHR10751:SF113; GUANYLATE-BINDING PROTEIN 1; 1.
DR   Pfam; PF02263; GBP; 1.
DR   Pfam; PF02841; GBP_C; 1.
DR   SUPFAM; SSF48340; Interferon-induced guanylate-binding protein 1 (GBP1), C-terminal domain; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS51715; G_GB1_RHD3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Antiviral defense; Cell membrane; Cytoplasm;
KW   Cytoplasmic vesicle; Golgi apparatus; GTP-binding; Hydrolase; Immunity;
KW   Innate immunity; Isopeptide bond; Lipoprotein; Membrane; Methylation;
KW   Nucleotide-binding; Prenylation; Reference proteome; Secreted;
KW   Ubl conjugation.
FT   CHAIN           1..589
FT                   /note="Guanylate-binding protein 1"
FT                   /id="PRO_0000190963"
FT   PROPEP          590..592
FT                   /note="Removed in mature form"
FT                   /evidence="ECO:0000305|PubMed:8830800"
FT                   /id="PRO_0000396777"
FT   DOMAIN          35..278
FT                   /note="GB1/RHD3-type G"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01052"
FT   REGION          1..311
FT                   /note="GTPase domain (Globular)"
FT                   /evidence="ECO:0000305|PubMed:10676968"
FT   BINDING         45..52
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:10676968,
FT                   ECO:0000269|PubMed:10970849, ECO:0000269|PubMed:16511497,
FT                   ECO:0007744|PDB:1F5N, ECO:0007744|PDB:2B8W,
FT                   ECO:0007744|PDB:2B92, ECO:0007744|PDB:2D4H"
FT   BINDING         67..69
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:10676968,
FT                   ECO:0000269|PubMed:10970849, ECO:0000269|PubMed:16511497,
FT                   ECO:0007744|PDB:1F5N, ECO:0007744|PDB:2B8W,
FT                   ECO:0007744|PDB:2B92, ECO:0007744|PDB:2D4H"
FT   BINDING         97..101
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:10676968,
FT                   ECO:0000269|PubMed:10970849, ECO:0007744|PDB:1F5N"
FT   MOD_RES         589
FT                   /note="Cysteine methyl ester"
FT                   /evidence="ECO:0000305|PubMed:8830800"
FT   LIPID           589
FT                   /note="S-farnesyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:29144452,
FT                   ECO:0000269|PubMed:31268602, ECO:0000269|PubMed:8830800"
FT   CROSSLNK        207
FT                   /note="(Microbial infection) Glycyl lysine isopeptide (Lys-
FT                   Gly) (interchain with G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:29144452"
FT   CROSSLNK        209
FT                   /note="(Microbial infection) Glycyl lysine isopeptide (Lys-
FT                   Gly) (interchain with G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:29144452"
FT   CROSSLNK        210
FT                   /note="(Microbial infection) Glycyl lysine isopeptide (Lys-
FT                   Gly) (interchain with G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:29144452"
FT   CROSSLNK        382
FT                   /note="(Microbial infection) Glycyl lysine isopeptide (Lys-
FT                   Gly) (interchain with G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:29144452"
FT   CROSSLNK        562
FT                   /note="(Microbial infection) Glycyl lysine isopeptide (Lys-
FT                   Gly) (interchain with G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:29144452"
FT   CROSSLNK        567
FT                   /note="(Microbial infection) Glycyl lysine isopeptide (Lys-
FT                   Gly) (interchain with G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:29144452"
FT   CROSSLNK        573
FT                   /note="(Microbial infection) Glycyl lysine isopeptide (Lys-
FT                   Gly) (interchain with G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:29144452"
FT   CROSSLNK        587
FT                   /note="(Microbial infection) Glycyl lysine isopeptide (Lys-
FT                   Gly) (interchain with G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:29144452"
FT   VARIANT         78
FT                   /note="I -> V (in dbSNP:rs1048401)"
FT                   /id="VAR_033950"
FT   VARIANT         166
FT                   /note="E -> D (in dbSNP:rs17130717)"
FT                   /id="VAR_033951"
FT   VARIANT         349
FT                   /note="T -> S (in dbSNP:rs1048425)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1715024, ECO:0000269|Ref.2"
FT                   /id="VAR_014849"
FT   VARIANT         409
FT                   /note="A -> G (in dbSNP:rs1048443)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1715024, ECO:0000269|Ref.2"
FT                   /id="VAR_046550"
FT   MUTAGEN         48
FT                   /note="R->A: Abolished GTPase activity."
FT                   /evidence="ECO:0000269|PubMed:28645896,
FT                   ECO:0000269|PubMed:29144452"
FT   MUTAGEN         51
FT                   /note="K->A: Loss of GTPase activity. Constitutively
FT                   monomeric. Expressed throughout the cytoplasm, loss of
FT                   vesicular accumulation. Impaired ability to promote
FT                   pyroptosis in response to T.gondii infection."
FT                   /evidence="ECO:0000269|PubMed:31268602,
FT                   ECO:0000305|PubMed:21151871"
FT   MUTAGEN         76
FT                   /note="K->A: Abolished GDPase activity."
FT                   /evidence="ECO:0000269|PubMed:28645896"
FT   MUTAGEN         184
FT                   /note="D->N: Strongly decreased nucleotide-binding."
FT                   /evidence="ECO:0000269|PubMed:29144452"
FT   MUTAGEN         207
FT                   /note="K->R: In 8KR mutant; abolished ubiquitination by S.
FT                   flexneri IpaH9.8 when associated with R-209, R-210, R-382,
FT                   R-562, R-567, R-573 and R-587."
FT                   /evidence="ECO:0000269|PubMed:29144452"
FT   MUTAGEN         209
FT                   /note="K->R: In 8KR mutant; abolished ubiquitination by S.
FT                   flexneri IpaH9.8 when associated with R-207, R-210, R-382,
FT                   R-562, R-567, R-573 and R-587."
FT                   /evidence="ECO:0000269|PubMed:29144452"
FT   MUTAGEN         210
FT                   /note="K->R: In 8KR mutant; abolished ubiquitination by S.
FT                   flexneri IpaH9.8 when associated with R-207, R-209, R-382,
FT                   R-562, R-567, R-573 and R-587."
FT                   /evidence="ECO:0000269|PubMed:29144452"
FT   MUTAGEN         227..228
FT                   /note="RK->EE: Constitutively dimeric. Localizes at
FT                   vesicle-like structures at the plasma membrane."
FT                   /evidence="ECO:0000269|PubMed:21151871,
FT                   ECO:0000269|PubMed:31268602"
FT   MUTAGEN         382
FT                   /note="K->R: In 8KR mutant; abolished ubiquitination by S.
FT                   flexneri IpaH9.8 when associated with R-207, R-209, R-210,
FT                   R-562, R-567, R-573 and R-587."
FT                   /evidence="ECO:0000269|PubMed:29144452"
FT   MUTAGEN         562
FT                   /note="K->R: In 8KR mutant; abolished ubiquitination by S.
FT                   flexneri IpaH9.8 when associated with R-207, R-209, R-210,
FT                   R-382, R-567, R-573 and R-587."
FT                   /evidence="ECO:0000269|PubMed:29144452"
FT   MUTAGEN         567
FT                   /note="K->R: In 8KR mutant; abolished ubiquitination by S.
FT                   flexneri IpaH9.8 when associated with R-207, R-209, R-210,
FT                   R-382, R-562, R-573 and R-587."
FT                   /evidence="ECO:0000269|PubMed:29144452"
FT   MUTAGEN         573
FT                   /note="K->R: In 8KR mutant; abolished ubiquitination by S.
FT                   flexneri IpaH9.8 when associated with R-207, R-209, R-210,
FT                   R-382, R-562, R-567 and R-587."
FT                   /evidence="ECO:0000269|PubMed:29144452"
FT   MUTAGEN         584..586
FT                   /note="RRR->AAA: Abolished localization to
FT                   pathogen-containing vacuoles."
FT                   /evidence="ECO:0000269|PubMed:29233899"
FT   MUTAGEN         584..586
FT                   /note="Missing: Abolished localization to
FT                   pathogen-containing vacuoles."
FT                   /evidence="ECO:0000269|PubMed:29233899"
FT   MUTAGEN         587
FT                   /note="K->R: In 8KR mutant; abolished ubiquitination by S.
FT                   flexneri IpaH9.8 when associated with R-207, R-209, R-210,
FT                   R-382, R-562, R-567 and R-573."
FT                   /evidence="ECO:0000269|PubMed:29144452"
FT   MUTAGEN         589..592
FT                   /note="Missing: Loss of association with membranes."
FT                   /evidence="ECO:0000269|PubMed:21151871"
FT   MUTAGEN         589
FT                   /note="C->S: Abolished farnesylation and recruitment to the
FT                   pathogen-containing vacuoles or vacuole-escaped bacteria.
FT                   Impaired ability to promote pyroptosis in response to
FT                   T.gondii infection."
FT                   /evidence="ECO:0000269|PubMed:29144452,
FT                   ECO:0000269|PubMed:31268602"
FT   STRAND          11..17
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   STRAND          20..23
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           25..32
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   STRAND          36..46
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           47..49
FT                   /evidence="ECO:0007829|PDB:1DG3"
FT   HELIX           51..58
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   STRAND          62..65
FT                   /evidence="ECO:0007829|PDB:2B8W"
FT   STRAND          70..72
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   STRAND          77..84
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   STRAND          86..88
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   STRAND          92..98
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   TURN            101..103
FT                   /evidence="ECO:0007829|PDB:1DG3"
FT   HELIX           104..106
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           112..122
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   STRAND          124..132
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           136..140
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           143..146
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           148..151
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   STRAND          156..158
FT                   /evidence="ECO:0007829|PDB:2D4H"
FT   HELIX           167..170
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           171..174
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   STRAND          177..183
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   STRAND          192..194
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           198..205
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           214..229
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   STRAND          233..237
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           244..252
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           255..257
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           260..276
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   TURN            283..285
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           290..306
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           312..342
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           350..371
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           376..378
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           379..423
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   TURN            424..427
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           432..449
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           457..467
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           469..478
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   STRAND          480..482
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           484..563
FT                   /evidence="ECO:0007829|PDB:1F5N"
FT   HELIX           566..582
FT                   /evidence="ECO:0007829|PDB:1F5N"
SQ   SEQUENCE   592 AA;  67931 MW;  3A06741218360732 CRC64;
     MASEIHMTGP MCLIENTNGR LMANPEALKI LSAITQPMVV VAIVGLYRTG KSYLMNKLAG
     KKKGFSLGST VQSHTKGIWM WCVPHPKKPG HILVLLDTEG LGDVEKGDNQ NDSWIFALAV
     LLSSTFVYNS IGTINQQAMD QLYYVTELTH RIRSKSSPDE NENEVEDSAD FVSFFPDFVW
     TLRDFSLDLE ADGQPLTPDE YLTYSLKLKK GTSQKDETFN LPRLCIRKFF PKKKCFVFDR
     PVHRRKLAQL EKLQDEELDP EFVQQVADFC SYIFSNSKTK TLSGGIQVNG PRLESLVLTY
     VNAISSGDLP CMENAVLALA QIENSAAVQK AIAHYEQQMG QKVQLPTETL QELLDLHRDS
     EREAIEVFIR SSFKDVDHLF QKELAAQLEK KRDDFCKQNQ EASSDRCSAL LQVIFSPLEE
     EVKAGIYSKP GGYRLFVQKL QDLKKKYYEE PRKGIQAEEI LQTYLKSKES MTDAILQTDQ
     TLTEKEKEIE VERVKAESAQ ASAKMLQEMQ RKNEQMMEQK ERSYQEHLKQ LTEKMENDRV
     QLLKEQERTL ALKLQEQEQL LKEGFQKESR IMKNEIQDLQ TKMRRRKACT IS
//
